Week in Review - ChinaBio® Today

Recent Articles

The Week in Review: China Pharma IPOs Raise $5.4 Billion in 12 Months Jul 24, 2010: China life science IPOs raised $5.4 billion in the last 12 months, led by the $1.3 billion IPO of Sinopharm Group; China’s central government spent $11.8 billion on healthcare reform in the first half of 2010; CCBI Healthcare Fund made an investment in Shanghai Kindly Enterprise Development Group; Lijun International Pharmaceutical set up a Joint Venture with Tonghua Dongbao Pharma in Jilin Province; BioHorizons has asked the SFDA for approval of its dental implant products; BMP Sunstone rose more than 10% on Monday on rumors it would be acquired; Lee's Pharma will be the exclusive China distributor for Remodulin, a United Therapeutics product; Beike Biotechnology opened a rehabilitation center in Romania; Novartis reported the SFDA has approved China use of Rasilez®, a treatment for high blood pressure; and Bayer Schering AG and The People’s Liberation Army General Hospital (301 Hospital) of Beijing have begun a research collaboration to study women’s health. More details....

Stock Symbols: (HKEX: 0939) (HKEX: 02005) (SHEX: 600867) (NSDQ: BJGP) (GEM: 8221) (NSDQ: UTHR) (NYSE: NVS)

The Week in Review: Charles River/Wuxi PharmaTech Back in the News Jul 17, 2010: Charles River Labs and WuXi PharmaTech (药明康德) expect their merger to produce up to $100 million in increased revenues by cross-selling and $20 million in cost savings; WuXi PharmaTech reported upbeat Q2 financial results; Fosun Pharma and Grupo Chemo of Spain will invest $73.8 million to develop four monoclonal antibody drugs; China PharmaHub will seek foreign biotech and medical device technology for acquisition by Sichuan companies; Merck Sharp & Dohme started construction of a $162 million drug packaging plant in Hangzhou; IBM collaborated with Peking University People's Hospital to build an evidence-based patient record system; Dehaier Medical Systems acquired a line of emergency ventilators from Beijing Qiumanshi Technology Co.; NeoStem received a grant to study a topically applied stem cell wound healing product; and Shandong Lukang Pharma expects a first half profit increase of 700%. More details....

Stock Symbols: (NYSE: CRL) (NYSE: WX) (SHEX: 600196) (OTCBB: WRLC) (NYSE: MRK) (NYSE: IBM) (NSDQ: DHRM) (NYSE Amex: NBS) (SHEX: 600789)

The Week in Review: More CRO Consolidation Jul 10, 2010: Venturepharm Lab signed a letter of intent with an unnamed “large multinational healthcare company” to form a clinical CRO joint venture; the largest 100 China pharmas are increasing their share of China drug market; China Animal Healthcare raised $45 million to expand its vaccine business; Artepharm Global announced a $10 million anti-malaria project in Africa; HEGLN (Dalian) Pharma paid $2 million to acquire a non-invasive urologic diagnostic technology; and Swedish Orphan Biovitrum partnered with Tonghua Dongbao Pharma (see story) to market each other’s products. More details…

Stock Symbols: (SI: CAHC) (OTCBB: ARGC) (STO: SOBI) (SHEX: 600867)

The Week in Review: ChinaBio® Partnering Forum Jul 3, 2010: Representatives of 337 companies from 23 countries attended the successful Second Annual ChinaBio® Partnering Forum 2010 in Suzhou, China; Fountain Medical Development and ICON plc will jointly operate a central lab facility in Tianjin; Zhejiang Huahai Pharma will spin off its US generic drug business; China PharmaHub set up a JV built around new technology for humanizing antibodies; NeoStem raised $5 million in a private placement; ULURU out-licensed the China rights for its wound healing product to Jiangxi Aiqilin Pharma; and China Nuokang Bio-Pharmaceutical struck a deal to register and distribute Dianatal® Obstetric Gel in China. More details...

Stock Symbols: (NSDQ: ICLR) (SHEX: 600521) (NYSE Amex: NBS) (NYSE Alternext: ULU) (NSDQ: NKBP)

The Week in Review: Medical Device Company to IPO in Hong Kong Jun 26, 2010: Trauson (Jiangsu) Holdings, an orthopedic products company, will stage a $98 million IPO in Hong Kong; Shandong Lukang Pharma will invest 3.5 billion RMB ($514 million) in a biomedical park; the Charles River Labs and WuXi PharmaTech tie-up could face regulatory opposition in China; Jiangsu Kanion Pharma bought an additional 33% stake in Nanxing Pharma; Johnson & Johnson is rumored to be involved in the most recent SFDA bribery scandal; Stallergenes announced a positive China Phase III trial of an asthma drug; Cellonis Biotech said its stem cell therapy shows promise as a diabetes treatment; and Renhuang Pharma will launch a TCM anti-depressant. More details…

Stock Symbols: (SHEX: 600789) (NYSE: CRL) (NYSE: WX) (SHEX: 600557) (NYSE: JNJ) (OTCPK: RHGP)

The Week in Review: Deals and Other News Jun 19, 2010: Sino Biopharmaceutical raised $79 million for a single, undisclosed, acquisition; Chindex formed a medical device distribution JV with Fosun Pharma; Charles River Labs defended its $1.6 billion acquisition of WuXi PharmaTech; BioSpectrum released its 2010 Survey of the Asia Pacific life science industry; Kun Run Biotech received SFDA manufacturing approval for a hepatitis B drug; India prohibited the importation of APIs from 10 China companies; China scientists have developed a Helicobacter pylori vaccine; Zhang Jingli, Deputy Director of the SFDA, has been fired; and Hutchison China MediTech jumped 10% on Friday without releasing any news. More details…

Stock Symbols: (HK: 1177) (NSDQ: CHDX) (SHA: 600196) (NYSE: CRL) (NYSE: WX) (OTCBB: KURU) (AIM: HCM)

The Week in Review: Transactions and Approvals Jun 12, 2010: Qiming Venture Partners announced a 250 million RMB ($36.7 million) fund to develop Beijing biomedical companies; Jana Partners will try to stop Charles River Labs’ acquisition of WuXi PharmaTech; Anhui Anke Biotech paid 7 million RMB ($1 million) for a 70% stake in Zhejiang Fuwei Pharma; Simcere (先声药业) will increase its ownership of Boda Pharma to 90%; Beike Biotech formed a JV with SiriCell Technologies of Bangkok; TauRx Pharma and Bayer will collaborate to develop diagnostic tools for Alzheimer’s; China Medical Technologies (中国医疗技术公司) received SFDA approval for its HPV test; Roche’s Tarveca increased survival among patients with a form of non-small cell lung cancer (NSLC) common in Asian patients; and Beike Biotech reported early success for umbilical cord mesenchymal stem cell transplants. More details…

Stock Symbols: (NYSE: CRL) (NYSE: WX) (SZEX: 300009) (NYSE: SCR) (XETRA: BAY) (NSDQ: CMED) (SVX: ROG)

The Week in Review: China Working on Biotech Development Plan Jun 6, 2010: China is close to finalizing a draft proposal of a five-year plan for developing its biotech industry; Pfizer agreed to sell its China swine vaccine business to Harbin Pharmaceutical Group for $50 million; Huiheng Medical will buy Portola Medical and its breast brachytherapy system; Mindray Medical licensed patient monitoring technology from Pulsion Medical; Tiantan Biological is building a 2.7 billion RMB ($400 million) vaccine facility in the BDA; and Sinovac won a major contract for its hepatitis A vaccine, Healive®. More details…

Stock Symbols: (NYSE: PFE) (SHEX: 600664) (OTCBB: HHGM) (NYSE: MR) (SHSE: 600161) (NSDQ: SVA)

The Week in Review: ChinaBio® Investor Forum Showcases Young Companies May 29, 2010: The 8th ChinaBio® Investor Forum, held in Shanghai, gave “Most Promising Company” awards to three young China life science companies; Hainan Honz Pharmaceutical Co. staged a $238 Million IPO in Shanghai; Charles River Laboratories defended its $1.6 billion purchase of WuXi PharmaTech (药明康德); Radient Pharma announced new plans to divest its rogue China subsidiary; Hemispherx Biopharma and China CRO Fountain Medical Development will seek SFDA approval of Hemispherx’s flu drug; Dehaier Medical Systems will distribute Heyer Medical’s line of ultrasonic nebulizers; Astellas Pharma of Japan will bulk up its sales force to help double its China sales; and Smith & Nephew opened a new 10,000 square meter manufacturing plant in Beijing this week. More details…

Stock Symbols: (GEM: 300086) (NYSE: CRL) (NYSE: WX) (NYSE AMEX: RPC) (AMEX: HEB) (NSDQ: DHRM) (NYSE: SNN)

The Week in Review: A Week of Deals May 22, 2010: Sichuan Kelun Pharma will raise 5 billion RMB ($735 million) in an IPO on the Shenzhen exchange; GanLee Pharma of Beijing received a $15 million investment from Qiming Venture Partners; OriGene Technologies will build a large monoclonal antibody production facility in Wuxi; Beijing Genomics Institute will locate its European headquarters in Copenhagen; Tianjin Tasly Pharma formed a biological drug JV with Transgene of France; Simcere Pharma (先声药业) wants to sell its OTC drug division as it makes deals to add prescription products; GeneNews signed up GeneDiagnostics to market its colorectal cancer test in China; and GlaxoSmithKline will cut prices in China to gain market share. More details…

Stock Symbols: (SZEX: 002422) (NYSE:SCR) (NYSE: GSK)